Диссертация (1139842), страница 20
Текст из файла (страница 20)
21. – №. 2. –С. 167-177.113.Goicoechea M, Martin J, De Sequera P. et al. Role of cytokines in theresponse to erythropoietin in hemodialysis patients // Kidney international. –1998. – Т. 54. – №. 4. – С. 1337-1343.114.Gray L. K., Smyth, K. A., Palmer, R. M. et al. Heterogeneity in olderpeople: examining physiologic failure, age, and comorbidity // Journal of theAmerican Geriatrics Society. – 2002. – Т. 50.
– №. 12. – С. 1955-1961.115.Groenveld HF, JanuzziJL, Damman K et al. Anemia and mortality inheart failure patients: a systematic review and meta-analysis // Journal of theAmerican College of Cardiology. – 2008. – Т. 52. – №. 10. – С. 818-827.116.Grote Beverborg N., van der Wal, H. H., Klip, I. T et al. High serumerythropoietin levels are related to heart failure development in subjectsfrom the general population with albuminuria: data from PREVEND //European journal of heart failure.
– 2016. – Т. 18. – №. 7. – С. 814-821.117.Guillem F., Lawson S., Kannengiesser C., et al. Two nonsensemutations in the TMPRSS6 gene in a patient with microcytic anemia andiron deficiency // Blood. – 2008. – Т. 112. – №. 5. – С. 2089-2091.118.Guo L., Wang, A. H., Sun, Y. L. et al. Serum erythropoietin levelpredicts the prognosis of chronic heart failure with or without anemia //115Experimental and therapeutic medicine. – 2013. – Т.
6. – №. 5. – С. 13271331.119.Hage C., Michaëlsson, E., Linde, C. et al. Inflammatory BiomarkersPredict Heart Failure Severity and Prognosis in Patients With Heart FailureWith Preserved Ejection FractionCLINICAL PERSPECTIVE: A HolisticProteomic Approach // Circulation: Cardiovascular Genetics. – 2017. – Т.10. – №. 1. – С. 1-12.120.Handelman G. J., Levin N. W. Iron and anemia in human biology: areview of mechanisms // Heart failure reviews. – 2008. – Т. 13.
– №. 4. – С.393-404.121.Heinrich P. C., Behrmann I., Serge H. A. et al. Principles ofinterleukin (IL)-6-type cytokine signalling and its regulation // Biochemicaljournal. – 2003. – Т. 374. – №. 1. – С. 1-20.122.Heymans S., Hirsch, E., Anker, S. D.et al. Inflammation as atherapeutic target in heart failure? A scientific statement from theTranslational Research Committee of the Heart Failure Association of theEuropean Society of Cardiology // European journal of heart failure. – 2009.– Т. 11. – №.
2. – С. 119-129.123.Ho K. K. L., Anderson, K. M., Kannel, W. B. et al. Survival after theonset of congestive heart failure in Framingham Heart Study subjects //Circulation. – 1993. – Т. 88. – №. 1. – С. 107-115.124.Hunter, H. N., Fulton, D. B., Ganz T et al. The solution structure ofhuman hepcidin, a peptide hormone with antimicrobial activity that isinvolved in iron uptake and hereditary hemochromatosis // Journal ofBiological Chemistry. – 2002. – Т. 277. – №. 40.
– С. 37597-37603.125.Inuzuka R., Abe J. Red blood cell distribution width as a link betweenineffective erythropoiesis and chronic inflammation in heart failure //Circulation Journal. – 2015. – Т. 79. – №. 5. – С. 974-975.126.Iversen P .O., Woldbaek P .R., Tonnessen Т . et al. Decreasedhematopoiesis in bone marrow of mice with congestive heart failure116//American Journal of Physiology-Regulatory, Integrative and ComparativePhysiology. – 2002. – Т. 282. – №. 1. – С. 166-172.127.Iyengar S., Abraham W. T.
Anemia in chronic heart failure: can EPOreduce deaths? // Cleveland Clinic journal of medicine. – 2005. – Т. 72. –№. 11. – С. 1027-1032.128.Jankowska E. A., Drozd M., Ponikowski P. Iron deficiency treatmentin patients with heart failure // Heart Failure. – Springer, Cham, 2017. – С.561-576.129.Jankowska E. A., Von Haehling, S., Anker, S.
D. et al. Iron deficiencyand heart failure: diagnostic dilemmas and therapeutic perspectives //European heart journal. – 2012. – Т. 34. – №. 11. – С. 816-829.130.Jelkmann W. Proinflammatory cytokines lowering erythropoietinproduction // Journal of Interferon & Cytokine Research. – 1998. – Т. 18. –№.
8. – С. 555-559.131.Jelkmann W. Regulation of erythropoietin production //The Journal ofphysiology. – 2011. – Т. 589. – №. 6. – С. 1251-1258.132.Jiang F., Sun Z.-Z., Tang Y.-T. et al. Hepcidin expression and ironparameters change in Type 2 diabetic patients // Diabetes research andclinical practice. – 2011. – Т. 93. – №.
1. – С. 43-48.133.Kaldara-Papatheodorou E. E., Terrovitis J. V., Nanas J. N. Anemia inheart failure // Polskie Archiwum Medycyny Wewnętrznej. – 2010. – Т.120. – №. 9. – С. 354-360.134.Kang C. K., Pope, M., Lang, C. C.et al. Iron deficiency in heartfailure: Efficacy and safety of intravenous iron therapy // Cardiovasculartherapeutics. – 2017.
– Т. 35. – №. 6. С. 1923-1938.135.Kemna E, Pickkers P, Nemeth E et al. Time course analysis ofhepcidin, serum iron, and plasma cytokine levels in humans injected withLPS // Blood. 2005.- Т. 106. - № 5.-С.1864–1866.117136.Kemna E. H., Tjalsma, H., Willems, H. L. et al. Hepcidin: fromdiscovery to differential diagnosis // Haematologica. – 2008.
– Т. 93. – №. 1.– С. 90-97.137.Kemna E., Pickkers, P., Nemeth, E. et al. Time-course analysis ofhepcidin, serum iron, and plasma cytokine levels in humans injected withLPS // Blood. – 2005. – Т. 106. – №. 5. – С. 1864-1866.138.Kishimoto T., Tanaka T. Interleukin 6 // Encyclopedia ofInflammatory Diseases.
– 2015. – С. 1-8.139.Klip IT, Comin‐Colet J,heart failure: An international pooled analysis // Am Heart J.- 2013.- №.165.– С. 575–582.140.Kokkinos P., Myers, J., Faselis, C. et al. Exercise capacity andmortality in older men: a 20-year follow-up study // Circulation. – 2010. – Т.122. – №. 8.
– С. 790-797.141.Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriureticpeptide levels in identifying patients with left ventricular systolic or diastolicdysfunction // Тhe American Journal of Medicine. 2001.- Т. 111.-№4. С.274-279.142.Kulaksiz H, Theilig F, Bachmann S et al. The iron-regulatory peptidehormone hepcidin: expression and cellular localization in the mammaliankidney // Journal of Endocrinology.
– 2005. – Т. 184. – №. 2. – С. 361-370.143.Lakhal-Littleton S, Wolna M, Carr CA et al. Cardiac ferroportinregulates cellular iron homeostasis and is important for cardiac function //Proceedings of the National Academy of Sciences.- 2015. – Т.112. – С.3164– 3169.144.Lang, R. M., Bierig, M., Devereux, R. B.at al. Рекомендации поколичественной оценке структуры и функции камер сердца //Echocardiography. – 2006. – Т. 7. – С.
79-108.145.Lankhorst C. E., Wish J. B. Anemia in renal disease: Diagnosis andmanagement // Blood Rev.- 2010. - №. 24.- С. 39–47.118146.Lecour S., James R.W. When are pro inflammatory cytokines SAFEin heart failure? // Eur. Heart J. - 2011. - Т 32.- №6.- С. 680–685.147.Leong W.
I., Lönnerdal B. Hepcidin, the recently identified peptidethat appears to regulate iron absorption // The Journal of nutrition. – 2004. –Т. 134. – №. 1. – С. 1-4.148.Leung D. D. M., Luan P., Manetta J. V. et al. Anti-ferroportin 1monoclonal antibodies and uses thereof : пат. 8183346 США.
– 2012.149.Levine B., Kalman J., Mayer I. et al. et al. Elevated circulating levelsof tumor necrosis factor in severe chronic heart failure // New EnglandJournal of Medicine. – 1990. – Т. 323. – №. 4. – С. 236-241.150.Lewis G. D., Semigran, M. J., Givertz, M. M. et al. Oral iron therapyfor heart failure with reduced ejection fraction: design and rationale for oraliron repletion effects on oxygen uptake in heart failure // Circulation: HeartFailure. – 2016. – Т. 9. – №.
5: 1-8.151.Lewis SM, Bain B, Bates I. Практическая и лабораторнаягематология. Пер. с англ. Румянцев А.Г., ред. М.: ГЭОТАР-Медиа;2009.152.Loreal O., Cavey T., Bardou-Jacquet E. et al. Iron, hepcidin, and themetal connection // Frontiers in pharmacology. – 2014. – Т. 5. – С. 128.153.Maggioni AP, Opasich C, Anand I, et al. Anemia in patients withheart failure: prevalence and prognostic role in a controlled trial and inclinical practice // Journal of cardiac failure. – 2005. – Т. 11. – №. 2.
– С.91-98.154.Mann D. L. Innate immunity and the failing heart: the cytokinehypothesis revisited // Circulation research. – 2015. – Т. 116. – №. 7. – С.1254-1268.155.Martínez-Ruiz A., Tornel-Osorio P.L., Sánchez-Más J. et al. SolubleTNFα receptor type I and hepcidin as determinants of development ofanemia in the long-term follow-up of heart failure patients // Clinicalbiochemistry. – 2012. – Т. 45. – №. 16-17. – С. 1455-1458.119156.Matsumoto M., Tsujino T., Lee-Kawabata M.et al. Iron regulatoryhormone hepcidin decreases in chronic heart failure patients with anemia //Circulation journal. – 2010.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
